The Effects of Different Physiotherapy Approaches in Stable COPD Patients.

April 13, 2022 updated by: Emine Korkmaz, Muğla Sıtkı Koçman University

The Effects of Kinesio Taping, Rigid Taping, Thoracic Mobilization and Core Stabilization Approaches on Respiratory Muscle Morphology, Respiratory Muscle Strength, Exercise Capacity and Quality of Life in Stable COPD Patients.

In our study, the effects of Kinesio Taping (KT), Rigid Taping (RT), Thoracic Mobilization (TM) and Core Stabilization (KS) approaches on respiratory muscle morphology, respiratory muscle strength, exercise capacity and quality of life will be examined in stable COPD patients. Study is designed as prospective, single-blinded, randomized-controlled study.

Study Overview

Detailed Description

The study is planned to compare the effects of different physiotherapy approaches on respiratory muscle morphology, respiratory muscle strength, exercise capacity and quality of life in stable COPD patients over 18 years of age.The study is carried out on 65 patients who applied to Muğla Training and Research Hospital with COPD patients. The patients are divided into 5 groups by randomization method. First group, Kinesio Taping group, inhibitory effect on upper trapezius and scalene muscles, facilitator effect on diaphragm and intercostal muscles will be applied. The second group, Rigid Taping group, inhibitory effect on upper trapezius and scalene muscles, facilitator effect on diaphragm and intercostal muscles will be applied. The third group,Thoracic Mobilization group, Modified Active-Passive Thoracic mobilization will be performed according to the patients' conditions. Thoracic Mobilization techniques will be used to improve thoracic mobility in the upper, middle or lower parts of the chest. The fourth group,In Core Stabilization group, five different trunk stabilization exercises will be performed. Fifth group is the control group and no taping was done. A standard treatment program is applied for the individuals in the whole group. Evaluations is made before and after treatment (3 and 6 weeks). Evaluation parameters is respiratory muscle morphology, respiratory muscle strength, exercise capacity and quality of life.

The respiratory muscle morphology is measured by the radiologist, and all other measurements and treatments were performed by the physiotherapist. Pulmonary function test will be measured using spirometry, respiratory muscle strength using mouth pressure device, functional exercise capacity using 6-minute walk test, quality of life using Leicester Cough Questionnaire, dyspnea using Modified Medical Research Council Dyspnea Scale and, symptoms using COPD Assessment Tests.

The data obtain from the research will be analyzed using the SPSS program. Statistical significance level will be accepted as p<0.05. In the statistical difference analysis between groups, one-way ANOVA test will be used for parametric data and Kruskal- Wallis test will be used for non-parametric data.

Study Type

Interventional

Enrollment (Anticipated)

65

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. People with stable COPD,
  2. Patients with spirometric measurements of GOLD 2-3 according to the new GOLD classification and A, B according to symptoms and exacerbations
  3. To be 18 years or older,
  4. No acute exacerbation in the last 3 weeks,
  5. Alterations in medical treatment and not using any antibiotics in last 3 weeks,
  6. Not being included in the pulmonary rehabilitation program in the last 6 months,
  7. Volunteering to participate in study

Exclusion Criteria:

  1. Orthopedic and neuromuscular disorders,
  2. Advanced heart failure,
  3. Aortic stenosis, deep vein thrombosis, pacemaker,
  4. Patients with acute exacerbation of symptoms in the previous three weeks,
  5. Those with weak cognitive function will be excluded from the study.
  6. Patients who are unable to cooperate will also be considered ineligible.
  7. Irritation, infection, allergic reaction, scarred burn or open wound around application area.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: intervention group 1
Kinesio taping and standard treatment program
Kinesio taping The intervention of this experimental study is therapeutic taping (kinesio tape) on the respiratory muscles of the participants.
Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises
Active Comparator: intervention group 2
Rigid taping and standard treatment program
Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises
Rigid taping The intervention of this experimental study is therapeutic taping (rigid tape) on the respiratory muscles of the participants.
Active Comparator: intervention group 3
Thoracic Mobilization and standard treatment program
Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises
Thoracic Mobilization The intervention of this experimental study is active-passive Thoracic mobilization techniques on the on the upper, middle or lower parts of the chest of the participants
Active Comparator: intervention group 4
Core Stabilization and standard treatment program
Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises
Core Stabilization The intervention of this experimental study is Core Stabilization exercises to the trunk muscles of the participants.
Other: Control group
No intervention, only standard treatment program
Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Respiratory muscle morphology
Time Frame: Change in muscle thickness at 6 week
Respiratory muscle morphology measurement will be made by the radiologist with the US imaging method. It will be applied to the diaphragm, intercostal muscles, upper trapezius and scalene muscles.
Change in muscle thickness at 6 week
Respiratory muscle strength
Time Frame: Change in MİP and MEP at 6 week

Maximum inspiratory pressure (Pimax) and maximum expiratory pressure (PEmax) will be evaluated using an electronic pressure transducer.Measurements will be made according to the guidelines of the American Thoracic Society/European Respiratory Society.

Pimax at residual volume and PEmax from Total lung capacity, Maximal inspiratory pressure will be determined by placing a nose clip instructed to exhale to residual volume followed by maximum inspiration.

To assess maximal expiratory pressure, the patient is instructed to inhale until total lung capacity is reached, followed by a forced exhalation. Three evaluations will be recorded and the best value will be used.

Change in MİP and MEP at 6 week
6-minute walk test
Time Frame: Change in distance at 6 week
It will be held in a 30 m barrier-free corridor. The measurement will be made according to the guidelines of the American Thoracic Society. The 6MWT will be repeated 2 times and the result will be given as a percentage of the predicted values. Patients will rest for 30 minutes between tests and the maximum distance will be recorded.
Change in distance at 6 week
Leicester Cough Questionnaire
Time Frame: Change in quality of life at 6 week
It consists of 19 items in 3 subcategories (physical, psychological, social) assessing the quality of life associated with chronic cough. Each question is evaluated using a 7-point Likert-type scoring system. The total score is obtained by summing the 3 sub-category scores. High scores are indicative of good quality of life.
Change in quality of life at 6 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modified Borg Scale
Time Frame: Change in dyspnea at 6 week
It is a scale used to evaluate the severity of dyspnea on exertion and the severity of dyspnea at rest. It consists of ten items describing the severity of dyspnea according to their degrees. 0 scales as no dyspnea, 10 as very severe dyspnea
Change in dyspnea at 6 week
COPD Assessment Test (CAT)
Time Frame: Change in healty status at 6 week
It was developed to measure the health status and to evaluate the disease effect and severity in COPD. The CAT consists of eight questions, covering problems such as shortness of breath, cough, sputum production, as well as symptoms such as fatigue and sleep problems. Perfect health: 0 points (minimum), worst health: 40 points. (max score)
Change in healty status at 6 week
Static and dynamic lung volumes Pulmonary Function Tests
Time Frame: Change in lung volumes at 6 week.
In order to evaluate pulmonary functions, FVC, FEV1, FEV1/FVC, Peak flow rate (PEF), 25-75% (FEF 25-75%) flow rate of forced expiratory volume will be taken in sitting position according to ATS/ERS criteria. Pulmonary function test parameters will be expressed as a percentage of actual values and expected values.
Change in lung volumes at 6 week.
Modified Medical Research Council
Time Frame: Change in perception of dyspnea at 6 week
The dyspnea scale will be used to evaluate the severity of dyspnea during activities of daily living. It will be graded from 0 (absence of dyspnea during strenuous exercise) to 4 (dyspnea during daily activities). The dyspnea perception scale will be questioned to what extent the patients have perceived dyspnea in daily activities in the last week.
Change in perception of dyspnea at 6 week
COPD and Asthma Fatigue Scale
Time Frame: Change in fatigue score at 6 week
The original scale consists of 12 items and a Likert-type scale (1=never, 2=rarely, 3=sometimes, 4=often, 5=very often) is used for responses. Scoring of the scale is in a five-point Likert type and a total value between 12 and 60 points is obtained.
Change in fatigue score at 6 week
Posture analysis
Time Frame: Change in posture at 6 week
"Posture Screen Mobile" mobile application will be used via smart phone to evaluate static posture.
Change in posture at 6 week
Chest anterior-posterior diameter measurement
Time Frame: Change in chest diameter at 6 week
Rib cage measurements Anterior and posterior diameter will be measured using a caliper.
Change in chest diameter at 6 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Baki Umut Tuğay, Muğla Sıtkı Koçman University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

April 18, 2022

Primary Completion (Anticipated)

March 15, 2023

Study Completion (Anticipated)

May 15, 2023

Study Registration Dates

First Submitted

April 13, 2022

First Submitted That Met QC Criteria

April 13, 2022

First Posted (Actual)

April 19, 2022

Study Record Updates

Last Update Posted (Actual)

April 19, 2022

Last Update Submitted That Met QC Criteria

April 13, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • physiotherapy approaches

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Clinical Trials on intervention group 1

Subscribe